URL: http://build.fhir.org/ig/HL7/vulcan-rwd/acs.htmlComment: I see that part of the evaluation is to identify ACS treatments (e.g., brand names of brilinta, effient, and plavix). As we know, different manufacturers, forms, etc., make up the RxNorm and, in particular, the NDC#, which is more widely used in retail pharmacies. So, for the RxNorm CUI, there's BN=Plavix 174742, and its IN/MIN = clopidogrel 32968. Let's double-check these and mention that an NDC equivalent may be referenced.
Add a column for NDCs and Health Canada DINs and a general statement about medication terminology being jurisdiction-specific and that the displayed codes are for IG testing purposes.
URL: http://build.fhir.org/ig/HL7/vulcan-rwd/acs.html Comment: I see that part of the evaluation is to identify ACS treatments (e.g., brand names of brilinta, effient, and plavix). As we know, different manufacturers, forms, etc., make up the RxNorm and, in particular, the NDC#, which is more widely used in retail pharmacies. So, for the RxNorm CUI, there's BN=Plavix 174742, and its IN/MIN = clopidogrel 32968. Let's double-check these and mention that an NDC equivalent may be referenced.
Here's one example of Plavix and its corresponding SPL results https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=PLAVIX
Further Note: Since IPS is used as the base, the terminology used can vary by region. Something to consider as a general statement.